Atezolizumab-bevacizumab combination provides ‘longest survival seen’ in advanced HCC

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.Richard S. Finn, MD, professor of medicine in the department of medicine, division of hematology/oncology, at David Geffen School of Medicine at UCLA, reported median OS of 19.2 months with atezolizumab (Tecentriq, Genentech/Roche) and bevacizumab (Avastin, Genentech) compared with 13.4 months with sorafenib (Nexavar, Bayer).“This is the longest survivalRead More

Share on facebook
Share on twitter
Share on linkedin